Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.97
Schlusskurs vom Vortag:
$4.97
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$48.77M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
0.00
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$25.10
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
What analysts say about bluebird bio Inc. stockExplosive earnings growth - jammulinksnews.com
What drives bluebird bio Inc. stock priceMarket-beating performance - Autocar Professional
Is bluebird bio Inc. a good long term investmentHigh-octane financial growth - jammulinksnews.com
What makes bluebird bio Inc. stock price move sharplyMomentum Buy Alert - beatles.ru
Unexpected Trends Reshaping the Adeno Associated Virus (AVV) - openPR.com
Sickle Cell Disease Treatment Market is Expanding at a CAGR - openPR.com
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Bluebird bio’s Long-Term Study on CALD Treatment: A Potential Game Changer - TipRanks
bluebird bio Expands Leadership Team - citybiz
bluebird bio Bolsters Management Team with Appointments - Contract Pharma
Inside the Future of the Gene Therapy for SCID Market: Forecasts, - openPR.com
Carlyle and SK Capital Complete Acquisition of bluebird bio - orrick.com
Bluebird bio Requests to Dismiss Class Action Filed by Investors - TradingView
Bank of America Corp DE Sells 1,358,195 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support - BioSpace
Adrenoleukodystrophy Treatment Market Overview | HSCT, Gene - openPR.com
Nuveen Asset Management LLC Decreases Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
BNP Paribas Financial Markets Decreases Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN
Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com
Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com
bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $47,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals
Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com
Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com
bluebird bio acquired to scale gene therapy access - Investing.com
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa
Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
The Gene Therapy Valuation Reset: A Strategic Investor's Opportunity in Bluebird Bio's Acquisition - AInvest
Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus
Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio - Investing.com India
Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus
Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):